All In Biotech

Drug Trial Radar · NCT06829784

TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection

A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQC2731 Injections in Patients With Poorly Controlled Severe Asthma

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 660 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

660

Planned (sponsor's estimate)

Start

Mar 21, 2025

Primary completion

Dec 2027

Study completion Mar 2028

Sponsor

Sponsor type
Industry
First posted
Feb 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of TQC2731 injection (420 mg Q4W) in adult subjects with inadequately controlled severe asthma. A total of 660 trial participants are expected to be enrolled, with trial participants randomized in a 1:1 ratio to receive either TQC2731 (420 mg Q4W) or placebo (Q4W) via subcutaneous (SC) administration.

Conditions

  • Asthma

Interventions

  • TQC2731 injectionDrug

    TQC2731 injection can specifically bind to the Thymic Stromal Lymphopoietin (TSLP) protein, blocking TSLP-dependent downstream signaling expression in engineered cells and inhibiting the production of inflammatory cytokines.

  • PlaceboDrug

    Placebo without drug substance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized incidence of asthma exacerbationsTime frame: From the first day of dosing to the completion of 52 weeks of treatment

Locations

101 sites in 1 country. Site status is shown where the registry gives one.

  • The People's Hospital of Bozhou

    Bozhou, Anhui, China · Not yet recruiting

  • Anhui Chest Hoispital

    Hefei, Anhui, China · Not yet recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Not yet recruiting

  • Lu'an People's Hospital of Anhui Province

    Lu'an, Anhui, China · Not yet recruiting

  • Tongling People's Hospital

    Tongling, Anhui, China · Not yet recruiting

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing No.6 Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Not yet recruiting

  • Zhangzhou Municipal Hospital of Fujian

    Zhangzhou, Fujian, China · Not yet recruiting

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China · Not yet recruiting

  • The Second Hospital & Clinical Medical School,Lanzhou University

    Lanzhou, Gansu, China · Not yet recruiting

  • The Eighth Afliated Hospital of Southern Medical University The First people's Hospital of Shunde

    Foshan, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Guangdong Provincial Hospital of Traditional Chinese Medicine

    Guangzhou, Guangdong, China · Not yet recruiting

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Third People's Hospital of Huizhou

    Huizhou, Guangdong, China · Not yet recruiting

  • Zhongshan City People's Hospital

    Zhongshan, Guangdong, China · Not yet recruiting

  • The Affiliated Hospital of Medical University

    Guilin, Guangxi, China · Not yet recruiting

  • Guilin People'S Hospital

    Guilin, Guangxi, China · Not yet recruiting

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China · Not yet recruiting

  • The First Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China · Not yet recruiting

  • Cangzhou Hospital of Integrated TCM-WM·Hebei

    Cangzhou, Hebei, China · Not yet recruiting

  • Xingtai People's Hospital

    Xingtai, Hebei, China · Not yet recruiting

  • Da Qing Long Nan Hospital

    Daqing, Heilongjiang, China · Not yet recruiting

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Not yet recruiting

  • The First Hospital of Qiqihar

    Qiqihar, Heilongjiang, China · Not yet recruiting

  • The People's Hospital of Anyang

    Anyang, Henan, China · Not yet recruiting

  • The Second People's Hospital of Jiaozuo City

    Jiaozuo, Henan, China · Not yet recruiting

  • Luo Yang Dong Fang People's Hospital

    Luoyang, Henan, China · Not yet recruiting

  • Xinxiang Central Hospital

    Xinxiang, Henan, China · Not yet recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Zhengzhou Central Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Zhoukou Central hospital

    Zhoukou, Henan, China · Not yet recruiting

  • Enshi Tujia and Miao Autonomous Prefecture Central Hospital

    Enshi, Hubei, China · Not yet recruiting

  • The Central Hospital of Wuhan

    Wuhan, Hubei, China · Not yet recruiting

  • Changsha Central Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University)

    Changsha, Hunan, China · Not yet recruiting

  • Loudi central hospital

    Loudi, Hunan, China · Not yet recruiting

  • Baotou Central Hospital

    Baotou, Inner Mongolia, China · Not yet recruiting

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.